Get regular updates to your inbox.
BAT4406F, an experimental treatment in the pipeline of Bio-Thera Solutions, reduced the number of circulating immune B-cells that produce disease-causing antibodies in neuromyelitis optica spectrum disorder (NMOSD), translating into less disability for a small group of Chinese patients. That’s according to data from a Phase 1 clinical…
Read more
Biologic immunosuppressants are more effective than conventional immunosuppressants for people with neuromyelitis optica spectrum disorder (NMSOD) with self-reactive antibodies against the AQP4 protein. That’s according to real-world data from a Japanese study comparing biologic therapies — Soliris (eculizumab), Enspryng (satralizumab), Ultomiris (ravulizumab), Uplizna (inebilizumab), and…
Having to deal with my sixth major neuromyelitis optica spectrum disorder (NMOSD) attack is not how I wanted to end 2024 or start the new year. Unfortunately, it’s just my reality. What’s considered an attack? It’s when your symptoms hit a high point. For NMOSD patients, that may…
NMOSD is a progressive autoimmune disease where the immune system mistakenly attacks nerve cells, affecting the nervous system. Learn more about the disease here.
Scientists do not know the exact underlying cause of NMOSD. Self-reactive antibodies that target AQP4 are known to play a major role. Learn more about what causes the disease here.
When the disease affects the optic nerve (optic neuritis), it can result in pain inside the eye and possibly blurry vision or vision loss. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
